Akatinol Memantine, 20 mg 98 pcs

Pharmacodynamics

As a non-competitive antagonist of N-methyl-D-aspartate (NMDA)-receptors it has modulatory effect on glutamatergic system. It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics

Akatinol Memantine is quickly and completely absorbed after oral administration. Maximum plasma concentration is reached within 2-6 hours. No cumulation of the drug is noted in normal renal function. Excretion is biphasic. Period of semiejection half-life is 4-9 hours in the first phase, and 40-65 hours in the second phase.
It is excreted in the urine.

Indications

Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.

Active ingredient

Composition

Active substance:

Memantine gilrochloride 20 mg;

Ancillary substances:

lactose,

MCC,

colloidal silica,

Talc,

Magnesium stearate,

Shell:

methacrylic acid copolymer,

sodium lauryl sulfate,

talk.

How to take, the dosage

Akatinol Memantine is taken orally, with meals. Dosing regimen is set individually. It is recommended to start treatment with prescription of the lowest effective dose.

In adults with dementia during the 1st week of therapy – in a dose of 5 mg/day, the 2nd week – in a dose of 10 mg/day, the 3rd week – in a dose of 15-20 mg/day. If necessary, further weekly dose increase by 10 mg to reach a daily dose of 30 mg.

The optimal dose is reached gradually, increasing the dose each week.

Interaction

Concomitant use with barbiturates, neuroleptics, anticholinergic agents may increase the effect of the latter. Co-administration may change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be adjusted individually.

Special Instructions

The optimal dose is reached gradually, increasing the dose each week.

Contraindications

With caution:

Side effects

Adverse reactions are classified according to their clinical manifestations (according to the involvement of certain organ systems) and their frequency of occurrence:

1Hallucinations have been observed primarily in patients with Alzheimer’s disease in the severe dementia stage.

2There have been anecdotal reports of these adverse reactions when the drug is used in clinical practice (data obtained after the drug was commercially available).

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Similarities